Invention Grant
US08383820B2 N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase 有权
N-金刚烷基苯甲酰胺作为11-&bgr-羟基类固醇脱氢酶的抑制剂

  • Patent Title: N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase
  • Patent Title (中): N-金刚烷基苯甲酰胺作为11-&bgr-羟基类固醇脱氢酶的抑制剂
  • Application No.: US12528229
    Application Date: 2008-02-19
  • Publication No.: US08383820B2
    Publication Date: 2013-02-26
  • Inventor: Soren Ebdrup
  • Applicant: Soren Ebdrup
  • Applicant Address: US NC High Point
  • Assignee: High Point Pharmaceuticals, LLC
  • Current Assignee: High Point Pharmaceuticals, LLC
  • Current Assignee Address: US NC High Point
  • Agent Samuel B. Rollins
  • Priority: EP07102956 20070223
  • International Application: PCT/EP2008/051971 WO 20080219
  • International Announcement: WO2008/101914 WO 20080828
  • Main IPC: A61K31/44
  • IPC: A61K31/44 A61K31/445 A61K31/40 C07D211/68 C07D207/00
N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase
Abstract:
Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
Information query
Patent Agency Ranking
0/0